Israeli scientists presented "data that seemed compelling in the 40 and up age range," Dr. Peter Marks, Director of the FDA's Center for Biologics Evaluation and Research said, speaking to the agency's Vaccines and Related Biological Products Advisory Committee.

(Reporting by Michael Erman, Editing by Franklin Paul)